SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE

• Main Authors: ARANI CHANDA, LIM KIAN HUAT, LIU XIANG, PARCHAREE TIVITMAHAISOON, BETTY CHAN, ENDO ATSUSHI, WANG JOHN, ARAI KENZO, GREGG F KEANEY, ZHENG GUO ZHU, SILVIA BUONAMICI, MURAI NORIO, BAUDOUIN GERARD, REGINA MIKIE KANADA SONABE, MICHAEL P THOMAS, NICHOLAS C GEARHART, SUDEEP PRAJAPATI, PETER G SMITH, KOTAKE YOSHIHIKO, NAGAO SATOSHI, YU LIHUA, KIRA KAZUNOBU, ERMIRA PAZOLLI, PARK EUNICE SUN, MIYANO MASAYUKI
• Format: Patent
• Language: English; Japanese
• Published: 19.07.2018
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use of the same.SOLUTION: A pharmaceutical composition comprises a crystalline form of (2S,3S,6S,7R,10R,E)-7, 10-dihydroxy-3,7-dimethyl-12-oxo- 2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4- methylpiperazine-1-carboxylate, and at least one additional component selected from pharmaceutically acceptable carriers, pharmaceutically acceptable excipients, and pharmaceutically acceptable additives.SELECTED DRAWING: None 【課題】プラジエノライドピリジン化合物の新規固体形態、少なくとも１つのこのような固体形態を含む組成物、及び調製の方法並びにそれの使用の提供。【解決手段】（２Ｓ，３Ｓ，６Ｓ，７Ｒ，１０Ｒ，Ｅ）−７，１０−ジヒドロキシ−３，７−ジメチル−１２−オキソ−２−（（Ｒ，２Ｅ，４Ｅ）−６−（ピリジン−２−イル）へプタ−２，４−ジエン−２−イル）オキサシクロドデカ−４−エン−６−イル４−メチルピペラジン−１−カルボキシレートの結晶形並びに医薬上許容しうる担体、医薬上許容しうる賦形剤、及び医薬上許容しうる添加剤から選択される少なくとも１つの追加の成分を含む、医薬組成物。【選択図】なし